Research programme: neurodegenerative disorder therapeutics - Noscira

Drug Profile

Research programme: neurodegenerative disorder therapeutics - Noscira

Alternative Names: NP-17; NP-901; NPM-05 family

Latest Information Update: 07 Mar 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuropharma
  • Developer Noscira
  • Class
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Amyloid precursor protein secretase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Neurological disorders

Most Recent Events

  • 18 Dec 2012 Noscira is in liquidation
  • 18 Dec 2012 Discontinued - Preclinical for Alzheimer's disease in Spain (PO)
  • 18 Dec 2012 Discontinued - Preclinical for Neurological disorders in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top